

HealthLinx Limited

OvPlex™ distribution expands into India

15 May 2012: HealthLinx Limited (ASX:HTX) with distribution partners INEX Innovations Exchange Pte Ltd. and Metropolis Healthcare Ltd. will begin selling OvPlex™ in India 3rd quarter 2012. OvPlex™ will be available in Mumbai, India from August 1, 2012, with extension of distribution to take place through all major Indian cities over the following six months.

Metropolis Healthcare Ltd. was founded by Dr. Sushil Shah in 1981. Metropolis Healthcare is India's leading multinational chain of 85 diagnostic centres and 600 collection centres across India, Sri Lanka, South Africa and Middle East.

This rapid expansion of jurisdictions in Asia in which OvPlex™ is available is prompted by excellent market acceptance and growth in Singapore and Malaysia where it has been on the market since October 2010. Since this time, INEX has exceeded expected sales targets by approximately 25% and continues to grow.

HealthLinx and its partners INEX and Metropolis Healthcare expect sales in India to grow rapidly over the next 6 months in one of the world's fastest growing and largest economies. HealthLinx and INEX are also exploring the opportunity of obtaining private insurance reimbursement on the test, and that should further increase sales.

"This expansion is an excellent result for women in India who will shortly have access to OvPlex™" said managing director Nick Gatsios. "As a company we are excited with INEX's proactive expansion strategies and management of both companies is working very closely to ensure further expansion occurs in a seamless, cohesive and timely manner."

Plans to expand into other jurisdictions to which INEX has an option in their distribution agreement, including Indonesia and Thailand will be announced in due course.

Enquiries

Nick Gatsios (HealthLinx Limited)	+61 3 9208 4200
Rudi Michelson (Monsoon Communications)	+61 3 9620 3333

About HealthLinx Limited (ASX:HTX)

HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality:

- Ovarian cancer diagnostic (OvPlex) targeting US\$270m pa market
- Prostate cancer targeting US\$350m pa market


A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.

ABN 88 098 640 352

576 Swan Street Richmond VIC 3121

Telephone: +61 3 9208 4200 | Facsimile: +61 3 9208 4201

www.healthlinx.com.au



HealthLinx Limited

HealthLinx has commenced the second larger study for OvPlex™ aiming to prove a diagnostic accuracy of over 97 per cent for early stage ovarian cancer. This larger study is based on 1150 new samples using existing OvPlex™ biomarkers and including two novel biomarkers AGR2 and HTX010. The study will be a robust comparison of sensitivity and specificity especially for early stage diagnosis in symptomatic women. The objective is to cement the position of OvPlex™ as the world's most accurate and efficient ovarian cancer diagnostic.

The second study is partially funded with \$750,000 from the Victorian Government Victoria's Science Agenda Investment Fund.

www.healthlinx.com.au

About INEX Private Limited

Established in June 2006, INEX Innovations Exchange Pte Ltd is a Singapore company focusing on cutting edge Molecular Diagnostics in women's health. INEX develops and distributes novel medical devices and diagnostics that save lives and better the health of women throughout the world.

In addition to distributing OvPlex™, INEX is currently the developer and global distributor of FlashFISH™ same day karyotyping for fetal abnormality and OvaCis™, a rapid intraoperative diagnostic test for Epithelial Ovarian Cancer. INEX is also the developer and exclusive licensee of next generation Non-Invasive Prenatal Diagnostic test utilizing DNA from Fetal Cells isolated from Maternal Blood.

About Metropolis Healthcare

Metropolis Healthcare Ltd. was founded by Dr. Sushil Shah in 1981. Metropolis Healthcare is India's leading multinational chain of 85 diagnostic centers and 600 collection centers across India, Sri Lanka, South Africa and Middle East. It provides around 4500 specialized tests under a single roof ranging from oncology to genetics, molecular biology and immunoassays using best-of-breed and latest diagnostic equipment. Ms. Ameera Shah has won prestigious award in 2nd CMO Asia Award as Young Achiever of the year'2011 & Entrepreneur India - Young Entrepreneur of the year 2011. eHealth World Expo 2011 – has also awarded Metropolis Healthcare Ltd as "Best Jury Award" for ICT enabled diagnostic service provider for the project IT integration of customer service management. Ms. Ameera Shah has recently been awarded by Dream companies to work for awards powered by Bloomberg I UTV - Women in leadership for the year 2012. In June 2010, Warburg Pincus, a leading global private equity firm, has invested up to \$85 million in Metropolis Healthcare Ltd.